{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:33:04Z","timestamp":1774582384370,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009414","name":"IOV IRCCS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009414","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.clgc.2023.04.006","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T04:20:06Z","timestamp":1681791606000},"page":"e378-e385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The prognostic Value of Thyroid Hormone Levels in Immunotherapy-Treated Patients With Metastatic Urothelial Carcinoma"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8483-0196","authenticated-orcid":false,"given":"Francesco","family":"Pierantoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3964-2866","authenticated-orcid":false,"given":"Michele","family":"Dionese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Basso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7726-1864","authenticated-orcid":false,"given":"Eleonora","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicol\u00f2","family":"Cavasin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Erbetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvise","family":"Mattana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Bimbatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorina","family":"Zagonel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6256-9249","authenticated-orcid":false,"given":"Marco","family":"Maruzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clgc.2023.04.006_bib0001","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.clgc.2023.04.006_bib0002","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1200\/JCO.19.00538","article-title":"Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: checkMate 032 nivolumab 1 mg\/kg plus ipilimumab 3 mg\/kg expansion cohort results","volume":"37","author":"Sharma","year":"2019","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clgc.2023.04.006_bib0003","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"10031","key":"10.1016\/j.clgc.2023.04.006_bib0004","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.clgc.2023.04.006_bib0005","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clgc.2023.04.006_bib0006","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.critrevonc.2019.08.005","article-title":"Immunotherapy and urothelial carcinoma: an overview and future prospectives","volume":"143","author":"Pierantoni","year":"2019","journal-title":"Critic Rev Oncol\/Hematol"},{"issue":"13","key":"10.1016\/j.clgc.2023.04.006_bib0007","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2023.04.006_bib0008","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8375348","article-title":"Predictive and prognostic role of PD-L1 in urothelial carcinoma patients with anti-PD-1\/PD-L1 therapy: a systematic review and meta-analysis","volume":"2020","author":"Liu","year":"2020","journal-title":"Dis Markers"},{"issue":"4","key":"10.1016\/j.clgc.2023.04.006_bib0009","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.eururo.2012.11.042","article-title":"Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials","volume":"63","author":"Sonpavde","year":"2013","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.clgc.2023.04.006_bib0010","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2009.25.4599","article-title":"Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens","volume":"28","author":"Bellmunt","year":"2010","journal-title":"JCO"},{"issue":"2","key":"10.1016\/j.clgc.2023.04.006_bib0011","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.clgc.2021.12.008","article-title":"Role of bone metastases in patients receiving immunotherapy for pre-treated urothelial carcinoma: the multicentre, retrospective meet-URO-1 bone study","volume":"20","author":"Raggi","year":"2022","journal-title":"Clin Genitourinary Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2023.04.006_bib0012","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2217\/imt-2021-0109","article-title":"Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group)","volume":"14","author":"Bersanelli","year":"2022","journal-title":"Immunotherapy"},{"issue":"11","key":"10.1016\/j.clgc.2023.04.006_bib0013","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1007\/s12094-020-02337-3","article-title":"Neutrophil-to-lymphocyte ratio and lactate dehydrogenase as biomarkers for urothelial cancer treated with immunotherapy","volume":"22","author":"Banna","year":"2020","journal-title":"Clin Transl Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2023.04.006_bib0014","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/JU.0000000000001199","article-title":"Five-factor prognostic model for survival of post-platinum patients with metastatic urothelial carcinoma receiving PD-L1 inhibitors","volume":"204","author":"Sonpavde","year":"2020","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.clgc.2023.04.006_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100118","article-title":"Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort","volume":"6","author":"Fornarini","year":"2021","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.clgc.2023.04.006_bib0016","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1210\/jc.2017-02149","article-title":"Degree of Peripheral Thyroxin Deiodination, Frailty, and Long-Term Survival in Hospitalized Older Patients","volume":"103","author":"Pasqualetti","year":"2018","journal-title":"J Clin Endocrinol\u00a0Metab"},{"issue":"3","key":"10.1016\/j.clgc.2023.04.006_bib0017","first-page":"e601","article-title":"Prognostic value of thyroid hormone ratios in patients with advanced metastatic colorectal cancer treated with regorafenib: the TOREADOR study","volume":"17","author":"Schirripa","year":"2018","journal-title":"Clin Colorectal Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2023.04.006_bib0018","doi-asserted-by":"crossref","first-page":"415","DOI":"10.5527\/wjn.v4.i3.415","article-title":"Low T3 syndrome and long-term mortality in chronic hemodialysis patients","volume":"4","author":"Fragidis","year":"2015","journal-title":"WJN"},{"issue":"1","key":"10.1016\/j.clgc.2023.04.006_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/JOE-09-0412","article-title":"Mechanisms behind the non-thyroidal illness syndrome: an update","volume":"205","author":"Warner","year":"2010","journal-title":"J Endocrinol"},{"issue":"1","key":"10.1016\/j.clgc.2023.04.006_bib0020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/bjh.14528","article-title":"Low T3 syndrome is a strong prognostic predictor in diffuse large B cell lymphoma","volume":"177","author":"Gao","year":"2017","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.clgc.2023.04.006_bib0021","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12672-014-0183-0","article-title":"Can non-thyroid illness syndrome predict mortality in lung cancer patients? A prospective cohort study","volume":"5","author":"Yasar","year":"2014","journal-title":"Horm Cancer"},{"key":"10.1016\/j.clgc.2023.04.006_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.787835","article-title":"Prognostic value of thyroid hormone ratio in patients with advanced metastatic renal cell carcinoma: results from the threefour study (Meet-URO 14)","volume":"11","author":"Maruzzo","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2023.04.006_bib0023","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejca.2020.04.023","article-title":"Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: results from the phase III randomised CORRECT trial","volume":"133","author":"Pasqualetti","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2023.04.006_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/6757154","article-title":"Thyroid hormones, oxidative stress, and inflammation","volume":"2016","author":"Mancini","year":"2016","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.clgc.2023.04.006_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.614030","article-title":"Thyroid hormones interaction with immune response, inflammation and non-thyroidal illness syndrome","volume":"8","author":"De Luca","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.clgc.2023.04.006_bib0026","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221094879","article-title":"The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy","volume":"14","author":"Alqaisi","year":"2022","journal-title":"Ther Adv Med Oncol"},{"issue":"9","key":"10.1016\/j.clgc.2023.04.006_bib0027","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.4158\/EP.14.9.1180","article-title":"Thyroid hormone therapy is not indicated in the majority of patients with the sick euthyroid syndrome","volume":"14","author":"Farwell","year":"2008","journal-title":"Endocr Pract"},{"issue":"4","key":"10.1016\/j.clgc.2023.04.006_bib0028","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s12032-017-0928-z","article-title":"Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients","volume":"34","author":"Buda-Nowak","year":"2017","journal-title":"Med Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323000940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323000940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:38:25Z","timestamp":1761565105000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767323000940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1558767323000940"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2023.04.006","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The prognostic Value of Thyroid Hormone Levels in Immunotherapy-Treated Patients With Metastatic Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2023.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}